Terminated MDLs: 2026

Long-running litigation involving defective drywall imported from China that released sulfur compounds, causing corrosion of metal components, electrical failures, and health issues in homes. Most claims were resolved through settlements with manufacturers and suppliers over the course of the litigation.

Antitrust litigation alleging major banks conspired to manipulate the London Interbank Offered Rate (LIBOR), affecting trillions of dollars in financial instruments. Multiple settlements were reached with defendant banks over the years, with the final remaining matters resolved.

Privacy litigation alleging TikTok collected and shared users' personal data without consent, including biometric data and information from minors. The case was resolved through a class action settlement providing compensation to affected users.

Wrongful death and personal injury claims arising from the crash of Sriwijaya Air Flight 182 into the Java Sea shortly after takeoff from Jakarta, killing all 62 people on board. Claims were resolved through settlements with Boeing and the airline.

Patent litigation related to the Xarelto blood thinner, involving disputes over the '310 patent. This companion MDL to the products liability case has been terminated following resolution of remaining patent disputes.

Litigation alleging that SoClean's ozone-based CPAP cleaning devices posed respiratory health risks and that the company made misleading marketing claims about the safety and efficacy of its products. Consumer claims were largely resolved through dismissals and settlements, with only 2 cases remaining at the time of termination. A related cross-claim by Philips seeking contribution toward its own CPAP settlement was severed into a separate civil action.

Class action litigation arising from a cyberattack on Evolve Bank & Trust that compromised customer personal information. Evolve agreed to an $11.85 million settlement providing affected class members with credit monitoring, reimbursement of up to $3,000 for documented losses, and a flat cash payment. Settlement payments were issued in March 2026.

Antitrust litigation alleging that Jazz Pharmaceuticals engaged in anticompetitive conduct to delay generic competition for Xyrem (sodium oxybate), a narcolepsy medication. Plaintiffs alleged Jazz used reverse-payment patent settlements with generic manufacturers and abuse of FDA processes to maintain monopoly pricing. Litigation was resolved with the remaining cases concluded as of May 2026.

Antitrust litigation alleging that major tire manufacturers conspired to fix prices for passenger vehicle replacement tires sold in the United States. Plaintiffs alleged coordinated price increases and information sharing among defendants. The MDL was terminated in May 2026 following resolution of the consolidated proceedings.